New Horizons in Alzheimer Research from Amyloid and Beyond
Abstract
(ISSN 2638-1311)
OBM Geriatrics is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Treatment of Dementia
Submission Deadline: November 30, 2019 (Closed) Submit Now
Guest Editor
Michael Fossel, MD, PhD
1. President of Telocyte (http://www.telocyte.com), Grand Rapids, MI 49503, USA
2. Retired Clinical Professor of Medicine, Michigan State University, Ada, MI 49301, USA
Research Interests: human aging; telomeres; telomerase therapy; age-related diseases; Alzheimer's disease
About This Topic
According to the recent report by the World Health Organization (WHO), as for the global dementia prevalence, the number of people with dementia in the world is now approximately 35.6 million. It is forecasted to increase to 39 million by 2050. Dementia is increasing worldwide, but more than half (58%) of the patients are concentrated in low- and middle-income countries, and this percentage will rise to more than 70% by 2050. The total cost of treating dementia and social loss worldwide is over 50 trillion yen (US $604 billion) per year. In this special feature, we will introduce efforts all over the world, and would like to outline the latest treatment of dementia in the world, in addition to pharmaceutical approaches, control over insulin resistance, diets, exercise, communication with others, mindfulness and other psychological approaches.
Planned Papers
Title: Palliative Care in Dementia- when is the appropriate time to intiate?
Authors: SC Lim and Edward Poon
Title: Forgotten: Narratives of Age-Related Dementia and Alzheimer’s Disease in Canada by Marlene Goldman, Book Review
Author: Julia Henderson, PhD
Title: Usefulness of the Long-Term Intermittent Hypoxic - Hyperoxic Training (IHHT) in Alzheimer’s type Dementia Treatment: Two Case Studies
Author: Arkadi F. Prokopov
Title: Parting with the concept of Alzheimer´s disease in senium.
Authors: Kalvach P., Vogner M.
Title: Multimodal Treatment for Dementia: Collaborative Research with the NHS, Functional Medicine and Lifestyle Change
Authors: Dr. Garuth Chalfont, Dr. Jane Simpson, Dr. Sarah Davies, Dr. Leigh Willoughby, Dr. David Morris, Professor Christine Milligan
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
New Horizons in Alzheimer Research from Amyloid and Beyondby
Jeffrey T. Apter
and
Kaylee M. White
Abstract The Amyloid and Tau Hypothesis of Alzheimer’s disease once thought to be the key have shown marginal results but are bolstered by the recent revival of the Aducanumab study and some positive data on some anti-Tau drugs. It still behoves us to look at other mechanisms which include whole blood transfusions, an Epigenetic approach, a-derivativ [...] |
Target Tau, not Amyloid, to Prevent and Treat Alzheimer’s DiseaseAbstract In this article I wish to put the case for a change of emphasis in the approach to finding a prevention/treatment for Alzheimer’s disease from a focus on beta amyloid to one on tau. In particular, I make the case for aiming to prevent the spread of abnormal tau from the medial temporal lobe to widespread areas of association cortex that [...] |
Intranasal Insulin in Alzheimer’s Disease: A Pragmatic AccountAbstract Pragmatic competence includes the capacity to express illocutionary force and successfully achieve perlocutionary effects, in order to guarantee fully functional communication exchanges. Improved pragmatic competence in patients has been found in patients with Mild Cognitive Impairment (MCI) and early to moderate Alzheimer’s Disease (AD [...] |
The Value Given and Presupposed in Person-Centred Dementia Careby
Stephen Ames
Abstract Thirty years ago, Tom Kitwood proposed a change in the care of people with dementia, from ‘warehousing’ to ‘person-centred care’. The change had noticeable benefits for those with dementia. Kitwood set out his presuppositions for this change. For example, Kitwood understood personhood as the standing or status bestowed on one human [...] |
Parting with the Concept of Alzheimer’s Disease in Seniumby
Pavel Kalvach
and
Martin Vogner
Abstract Our understanding of the mental deterioration associated with old-age have undergone a number of changes over the past two centuries and have spurred major scientific debates. In the 19th century, this disorder was still considered to be an inevitable feature of aging. The dawn of the 20th century offered a histological explanation for preseni [...] |
Treating Dementia Early: Limiting Cellular Damage in Brain TissueAbstract Much evidence has been published which indicates that microvascular endothelial dysfunction, due to cerebrovascular risk factors (e.g., atherosclerosis, hypertension, obesity, diabetes, smoking, aging), precedes cognitive decline in Alzheimer's disease and contributes to its pathogenesis. By incorporating appropriate drug(s) into biomimetic [...] |
Daily Observations of Preserved Cognition and Quality of Life after Multiple Therapies for Postmortem-Verified Severe Alzheimer’sby
Keith A. Wollen
and
John W. Hoyt
Abstract Abstract
Background: Cognitive abilities in Alzheimer’s Disease are usually examined by formal tests conducted in a laboratory or facility. Such tests are useful for determining the severity of the disease but do not indicate the types of cognition exhibited in the daily lives of patients. This study shows cognitive preservation in dail [...] |
Does Dementia Increase the Risk of Dental Decay?Abstract The amount of patients who suffer with dementia is set to rise with an ageing population living longer. As well as living longer, patients will be retaining
their natural teeth longer and will be less reliant on dentures.
From both the current evidence available in the literature, and anecdotally from clinicians experienced in treating [...] |
Key Dimensions of Therapeutic Lies in Dementia Care: A New TaxonomyAbstract Background:
Research suggests that the use of lies and deception is prevalent within dementia care settings, despite ongoing debates raised about the ethics of this approach. There has been increasing exploration of when and why deceptive practices should be used, but the lack of clarity as to what constitutes a lie has caused difficulty [...] |
Do Social Isolation and Loneliness Kill People with Alzheimer's Disease?by
Yoram Barak
and
Paul Glue
Abstract Patients with AD have shortened life expectancy than the general older population is well established. Loneliness may be another risk factor to consider if we wish to understand and improve the premature mortality of AD. |
TOP